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1. Introduction 
Antibody mediated rejection (AMR), also known as B-cell mediated rejection or humoral 
rejection, of the cardiac allograft was first clinically described in the late 1980’s (Herskowitz 
et al., 1987) followed shortly thereafter by pathologic evidence to support a unique rejection 
process apart from cellular mechanisms (Hammond et al., 1989). This is in contrast to the 
progression of knowledge regarding cellular rejection, or T-cell mediated rejection, which 
was readily described in the early 1960’s and is the target of most current maintenance 
immunosuppression agents. Unfortunately, AMR remains poorly understood due, in large 
measure, to its complicated presentation, pathophysiology, diagnosis, and treatment. The 
lack of clarity regarding AMR has been compounded by multiple small studies in varying 
populations with a multitude of treatment modalities and combinations. Additionally, 
several new agents have been recently utilized or hypothesized to be of utility, with varying 
success.  
Given the complexity of this process, lack of standardization in diagnosis, and multiple 
proposed treatment options, several professional organizations have endeavored to come to 
a consensus on the subject of AMR in heart transplant recipients. Most recently in 2011, the 
International Society for Heart and Lung Transplantation (ISHLT) published their outcomes 
from a consensus conference regarding AMR in heart transplantation (Kobashigawa et al., 
2011) as well as a breakout group working formulation regarding pathologic diagnosis of 
AMR in heart transplantation (Berry et al., 2011). While these two documents provide some 
direction for practitioners and transplant providers, many questions remained unanswered 
and the rapid evolution of novel therapies and strategies for treatment will likely change the 
field of AMR in the heart transplant population dramatically. 
This chapter will look to lay a foundational knowledge of the pathophysiology, 
epidemiology, and diagnosis of AMR. Additionally, traditional therapies are described and 
evaluated with a highlight on the controversies surrounding their use; finally, novel and 
experimental therapies along with their potential impact on prevention and treatment of 
AMR are described.  
2. Definitions 
Antibody mediated rejection can be characterized in several different ways. First, it can be 
qualified based upon the temporal relationship it has to transplantation. Hyperacute AMR is 
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a well known, well described process by which a patient has previously been exposed to 
some antigen that a donor expresses, and upon transplantation a rapid, immediate antibody 
response occurs leading to graft dysfunction and most often graft loss within 24 hours. 
Treatment of hyperacute AMR rarely reverses the process to salvage the graft. Acute AMR 
occurs sometime after the 24 hour postoperative period, and is generally rapid in onset; 
treatment strategies may be moderately effective. Chronic or late AMR is a newly 
recognized, poorly understood process that usually occurs greater than one year following 
transplantation and is thought to be very slow in progression with poor response to therapy. 
Additionally, AMR can be described as either occurring due to pre-sensitization or is the 
result of de novo antibody production. De novo AMR occurs when a recipient lacks donor 
specific antibodies (DSA) and has a negative cross-match at the time of transplant, but 
subsequently develops AMR at some point after transplantation. Alternatively, if a patient 
has been previously exposed to antigens that a donor expresses, they are said to be pre-
sensitized and typically receive prophylactic or empiric treatment in the peri-operative 
period. If, however, antibodies reappear at some point in the post-transplant period a 
renewed AMR may occur. 
3. Pathophysiology 
The immune system can generally be divided in to two main arms: the T cell, “cellular”, 
arm, and the B cell, “humoral”, arm. While these systems are complex and largely 
integrated, they do originate independently. B cells begin in the bone marrow as progenitor 
B cells and through activation by encounters with antigens mature through pro B cell, pre B 
cell, immature, and finally mature B cells. Activated mature B cells are also known as 
plasma cells and are essentially antibody factories. Antibodies are specific to a single 
antigen, such as proteins expressed on the surface of a transplanted organ, that are created 
to attach and signal other parts of the immune system to attack the foreign substance. This 
immune activation by antibody signaling ultimately damages the allograft. Damage is 
thought to occur via complement cascade-mediated fixation and activation, which actively 
damages the foreign material and also acts as a biochemical “amplifier”, signaling other 
parts of the innate and adaptive immune systems such as neutophils, pro-inflammatory 
molecules and cytokines for example, to relocate to the site of antibody adhesion and attack. 
One of the more unique aspects of the B cell arm of the immune system is that it retains 
memory. Once a person has been exposed to an antigen presenting cell (usually from a 
foreign physiologic source such as an organ or transfusion) and mounts an immune 
response, a memory B cell is created that, without active intervention, will always exist and 
will mount a more-rapid response to subsequent antigen presentation from the same source.  
These antigens can be portions of viruses, bacteria, or fungus. Human cells also express 
antigens; the most commonly identified of which are human leukocyte antigens (HLA). 
While a person does not usually attack itself and therefore tolerates their own HLAs, this is 
not true for other human tissues that express various antigens and are introduced in to a 
patient such as in solid organ transplantation. 
Subsequently, the risk factors for development of AMR include anything that exposes 
patients to other human products and therefore creates more potential memory cells to 
respond to a transplanted organ. These include pregnancies, blood and blood product 
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transfusions, repeat transplantation, and, specific to heart transplantation, the widespread 
and growing use of extracorporeal and intracorporeal mechanical circulatory support 
devices such as left ventricular assist systems (LVAS), bi-ventricular assist devices, total 
artificial hearts, extracorporeal membranous oxygenators (ECMO), or intra-aortic 
counterpulsators (Reed et al., 2006).  
AMR has recently been described as occurring across a spectrum, from completely 
asymptomatic circulating antibody to clinically overt organ rejection with hemodynamic 
compromise, graft loss, and decreased survival (Takemoto et al., 2004). Additionally, AMR 
has been described to contribute significantly to cardiac allograft vasculopathy (CAV), and 
often occurs in conjunction with acute cellular rejection as so-called mixed rejection 
(Montgomery et al., 2004). 
4. Epidemiology 
The true incidence of AMR has been difficult to define given the lack of standardization in 
diagnosis; however, it is generally accepted that AMR plays a much larger role in overall 
graft and patient survival than previously appreciated. The reported incidence of de novo 
AMR varies widely based upon the definitions used and at which point on the spectrum a 
study defines AMR. Epidemiologic studies in centers that perform protocolized 
endomyocardial biopsies have shown a wide variability in incidence of 3 – 51% (Michaels et 
al., 2003; Shahzad et al., 2011). Not surprisingly, those institutions that include circulating 
antibodies without evidence of graft dysfunction had a higher reported incidence of AMR.  
Additionally, as the boundaries of transplantation have been expanded in recent years, the 
number of patients who present for transplantation highly pre-sensitized to other human 
antigens is on the rise. Based on a survey of the patients who experienced AMR at some 
point after transplant from 46 heart transplant centers, 35% (114/324) of patients were pre-
sensitized prior to transplant, and of those 32% (37/114 ) were treated to attempt to reduce 
the amount of circulating antibodies prior to transplantation (Kobashigawa et al., 2011). 
5. Diagnosis 
Significant effort has been placed on standardizing the diagnosis of AMR of the cardiac 
allograft within the past 3 – 5 years. These efforts highlight that clinical factors, 
immunologic criteria, and pathologic criteria all play important roles. In 2004, a general 
staging of AMR was developed (Table 1), as were criteria for diagnosis of AMR in heart 
transplant recipients (Table 2). More recently, the ISHLT proposed a preliminary pathologic 
grading scheme similar to the 2004 guidelines (Table 3) with one major difference: the 
ISHLT workgroup recognized AMR as a diagnosis that can be made without evidence of 
circulating antibodies or clinical dysfunction.  
5.1 Immunologic screening 
Antibody screening tests have been clinically available for many years. These tests 
determine circulating antibody, but do not address very low level antibodies or antibodies 
that may be active but not in circulation. Prior to solid-phase antibody (SPA) testing, the 
presence of antibodies was determined utilizing cell-based assays. The mainstay of testing 
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 Circulating 
Antibody 
C4d 
Deposition 
Tissue 
Pathology 
Graft 
Dysfunction 
Stage I: Latent 
Humoral Response 
Present    
Stage II: Silent 
Humoral Rejection 
Present Present   
Stage III: Subclinical 
Humoral Rejeciton 
Present Present Present  
Stage IV. Humoral 
Rejection 
Present Present Present Present 
Table 1. General AMR staging 
 
Evidence of graft dysfunction Present 
Histologic evidence of tissue injury 
*Endothelial swelling or denudation 
*Macrophages in capillaries 
Neutrophils in capillaries 
Interstitial edema, congestion and/or 
hemorrhage 
Immunopathologic evidence for antibody 
action 
Ig G, M, and/or A  
C3d and/or C4d and/or C1q in capillaries 
Fibrin in vessels 
Serologic evidence of anti-HLA or other 
anti-donor antibody at time of biopsy 
Present 
* required histologic findings 
Table 2. 2004 diagnostic criteria of acute AMR in heart transplant recipients 
 
Category Description Definition 
pAMR 0 
Negative for 
pathologic AMR 
Both histologic and immunopathologic studies are 
negative 
pAMR 1 
(H+) 
Histopathologic 
AMR alone 
Histologic findings present and immunopathologic 
studies negative 
pAMR 1 
(I+) 
Immunopathologic 
AMR alone 
Histologic findings negative and immunopathologic 
findings positive 
pAMR 2 Pathologic AMR 
Both histologic and immunopathologic findings 
present 
pAMR 3 
Severe pathologic 
AMR 
Histologic findings of interstitial hemorrhage, 
capillary fragmentation, mixed inflammatory 
infiltrates, endothelial cell pyknosis, and/or 
karyorrhexis and marked edema 
Table 3. 2011 ISHLT criteria for pathologic AMR 
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was complement-dependent cytotoxicity (CDC) assays which involve incubating patient 
serum with cells of known HLA types, rabbit sera as a source of complement, and finally 
cell dyes to determine the amount of cell death that has occurred. The HLAs tested cover a 
very wide spectrum of known HLAs, however not all HLAs are tested. Limitations of this 
test included its lack of sensitivity and specificity (Berry et al., 2011). Unfortunately, the 
differences in clinical impact of circulating donor specific antibodies (DSAs), anti-HLA 
antibodies, or non-HLA antibodies, comparatively, have not been fully elucidated.  
5.1.1 Solid Phase Antibody detection 
The recent advent of SPA detection has revolutionized immunologic screening. The so-
called Luminex® (LABScreen, One Lambda Inc., Canoga Park, CA) single antigen bead 
(SAB) assay panel provides a comprehensive assessment of individualized IgG and IgM 
HLA antibodies present in the recipient using a multiplex platform (El-Awar et al., 2005). 
These beads are coated with fluorescein-tagged antigens, which fluoresce in the presence of 
the known HLA antibody. The degree of fluorescence, defined in units of mean equivalents 
of soluble fluorochrome or mean fluorescent intensity, is directly proportional to the 
circulating amount of the HLA antibody in question. This quantitation is critical when 
determining which antibodies to exclude from the potential donor pool, and during the 
depletion process of DSA in the post transplant period.  
Despite this improved specificity, the positive predictive value (PPV) of the Luminex assay for 
AMR remains poor (45%); however, the negative predictive value for AMR is quite good 
(100%) in a recent analysis (Chin et al., 2011). In an effort to improve the PPV of the Luminex-
SAB assay, the Immunogenetics Laboratory at Stanford University spiked an otherwise 
ordinary Luminex assay sample with purified human Complement-1q (C1q) and ran the 
sample. The results of the assay revealed a significant decrease in background antibodies, and 
focused the assay only on those HLA antibodies able to fix C1q. This addition improved the 
assay’s PPV, dramatically, to 100% (Chin et al., 2011). This technique is currently in its infancy, 
but may result in enhanced utility of the Luminex assay over the decade to come. 
5.2 Pathophysiology 
Endomyocardial biopsies (EMB) at many centers are routinely performed in addition to 
those performed for any patient who exhibits signs and symptoms of graft dysfunction. It 
has been recognized that findings seen on histology are unique from those seen with acute 
cellular rejection or CAV. Some consensus regarding the findings for AMR was established 
recently. Pathologic findings are almost exclusively found in the capillary beds; common 
findings in AMR include endothelial swelling or denudation, deposition of macrophages or 
neutrophils in capillaries, and interstitial edema, congestion, and potentially hemorrhage in 
severe cases. Immunopathologic findings include deposition of IgG, M, or A, and positive 
staining for byproducts of the complement cascade including Complement-3d (C3d), 
Complement-4d (C4d), or C1q in the capillaries. Sometimes fibrin may also be found in the 
vessel beds. Table 3 outlines the grading criteria for pathologic AMR staging. 
6. Treatment  
When discussing treatment options, there are two major divisions for which these therapies 
have been studied. The first is for the removal of circulating antibodies prior to 
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transplantation, a process known as desensitization; the second is for treatment of AMR, 
whether it be a reactivation of a previously sensitized patient or de novo AMR. 
Desensitization may be performed to either remove circulating antibody in the weeks to 
months prior to a transplant in an effort to allow for a larger donor pool in highly sensitized 
patients, or to mitigate the risk of AMR in the early postoperative period when a patient is 
known to have mismatched antigens such as is the case with ABO incompatible 
transplantation or positive cross-matches at the time of transplantation. Treatment may be 
performed at any point in the spectrum of AMR, from treatment of asymptomatic 
circulating antibodies to the treatment of clinically significant graft dysfunction caused by 
antibody-mediated activation of the immune system, with the goals of halting current 
damage, reverse signs and symptoms of AMR, and long-term to prevent the development of 
CAV and improve allograft and patient survival. Figure 1 contains a proposed treatment 
algorithm.  
 
Fig. 1. AMR treatment algorithm. CDC, complement dependent cytotoxicity. DSA, donor 
specific antibody. IVIg, intravenous immunoglobulins. rATG, rabbit anti-thymocyte 
globulin. TPE, plasmapheresis. 
6.1 Plasmapheresis 
Plasmapheresis, or plasma exchange, has been used clinically for a variety of autoimmune 
conditions since the early 1970’s and is generally considered a cornerstone for treatment of 
AMR. It is a process which physically removes circulating antibodies along with many other 
circulating proteins; generally 7 – 14 plasmapheresis sessions at varying intervals (from 
daily to every 3 – 4 days) are required for substantial removal of antibodies. Each session 
generally lasts 2 – 4 hours. It is an invasive procedure in which a large-bore central venous 
catheter must be placed and extracorporeal separation of blood occurs via either centrifuge 
or filtration, antibodies are removed and discarded, and finally blood is returned to the 
patient.  
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6.1.1 Plasmapheresis techniques 
Three main techniques can be utilized: therapeutic plasma exchange (TPE), double-filtration 
plasmapheresis (DFPP), and immunoadsorption plasmapheresis (IAPP). Therapeutic 
plasma exchange involves separation of red blood cells from plasma, complete removal of 
all plasma, and finally administration of exogenous fresh-frozen plasma or albumin to 
replace the plasma removed. In many centers, protocols require repletion with both albumin 
and fresh-frozen plasma on alternating days to replete coagulation factors removed that are 
not present in exogenous albumin preparations. Double-filtration plasmapheresis separates 
plasma from red blood cells in the first step, followed by a second filtration of the plasma 
that separates large molecules from small molecules and sera, and the small molecules and 
sera are then infused with the endogenous red blood cells. The final technique, 
immunoadsorption, is theoretically similar to DFPP, but utilizes an immunochemical 
reaction in the second step to remove only immunoglobulins. TPE and DFPP are older, more 
established techniques and relatively inexpensive; the immunoadsorbent membrane utilized 
with IAPP is quite expensive and removes only circulating immunoglobulins, potentially 
leaving signaling molecules for AMR such as cytokines in circulation. However, an 
advantage of IAPP is the avoidance of replacement colloids like albumin and fresh-frozen 
plasma and the adverse effects that are associated with these products; plasma exchange is 
the predominant method utilized at most US transplant centers.  
6.1.2 Data for plasmapheresis in heart transplantation 
Plasmapheresis has been utilized significantly in both desensitization protocols as well as in 
the treatment of AMR in all solid organ transplants as well as heart transplant recipients. 
Among sensitized patients awaiting transplantation, the preoperative use of plasmapheresis 
with intravenous immunoglobulins (IVIg) produced similar intermediate term outcomes of 
rejection and allograft survival compared to non-sensitized patients (Larson et al., 1999; 
Leech et al., 2006; Pisani et al., 1999). For the treatment of AMR, plasmapheresis has been 
utilized as part of a multi-treatment modality with success. In 2006, Wang and colleges 
reported moderate success with 5 days of daily plasma exchange for 12 symptomatic AMR 
cases in conjunction with methylprednisolone 1gm/day (Wang et al., 2006). In surveying 6 
major cardiac transplant centers, all report plasmapheresis as part of their initial 
management strategy for AMR. Unfortunately, no studies have compared therapy of AMR 
with or without plasmapheresis, so the actual contribution to good outcomes is impossible 
to determine at this point, however it is recommended as one of the first line strategies for 
treatment of AMR (Kobashigawa et al., 2011). 
6.1.3 Considerations with plasmapheresis use 
One major consideration with use of plasmapheresis is medication removal; medications 
that are highly protein-bound with low volumes of distribution will be readily removed by 
TPE or DFPP, and should be administered after the session is complete. In studies 
evaluating removal of medications in the setting of overdose, those medications with a Vd 
less than 0.2 L/kg and greater than 80% protein binding were most likely to be substantially 
removed (Sketris et al., 1984). Case reports have found minimal removal of calcineurin 
inhibitors, prednisone, or azathioprine (Balogun et al., 2001; Hale et al., 2000; Stigelman et 
al., 1984); however one case report of plasma exchange following administration of 
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basiliximab found significant removal (Okechukwu et al., 2001). Other agents with likely 
removal by plasma exchange of concern to transplant recipients include rituximab, (Darabi 
et al., 2006), vancomycin (Foral & Heineman 2001; Osman & Lew 1997; Sirvent & Borras-
Blasco 2006), levothyroxine (Binemelis et al., 1987; Liel et al., 2003), and aminoglycoside 
antibiotics (Kale-Pradhan et al., 1995; Ouellete et al., 1983; Appelgate et al., 1981). Regardless 
of likelihood of removal by plasma exchange, every effort should be made to administer 
critical medications following a session to ensure adequate exposure. 
6.2 Total Intravenous Immunoglobulins (IVIg) 
Total intravenous immunoglobulins are likely the most often utilized product for 
desensitization and treatment of AMR across solid organ transplantation including cardiac 
transplant recipients. IVIg was originally developed in the 1980’s as a replacement product 
for those patients with immune deficiencies, but anti-inflammatory and immunomodulatory 
effects were quickly understood. The actual mechanisms of immunomodulatory effects of 
IVIg have been widely postulated, however consensus has not been reached on exactly how 
IVIg may prevent or halt AMR; rather a “multi-hit” model has been proposed.  
6.2.1 Mechanisms of action 
Proposed mechanisms specific to the humoral immune system include increased apoptosis 
of B cells, neutralization of B cell survival signaling molecules, regulation of antibody 
production, and decreased B cell proliferation (Nimmerjahn & Ravetch 2008; Brandt & 
Gershwin 2006; Jordan & Toyoda 2009; Durandy et al., 2009). A multitude of mechanisms 
that affect other aspects of the immune system including T cells, neutrophils, NK cells, and 
so forth have been proposed as well. Dose-dependent effects have also been proposed, with 
low-doses (500 mg/kg) IVIg reported to have more pro-inflammatory effects whereas high-
doses (1 – 2 gm/kg) exhibit anti-inflammatory and more immunoregulatory effects. 
6.2.2 Data for IVIg in heart transplantation 
While IVIg is one of the most common agents used in AMR of the cardiac allograft, data are 
surprisingly limited for its use. Four main studies have evaluated the utility of IVIg for 
desensitization prior to cardiac transplantation. Similar to the data seen with other therapy 
modalities, IVIg has been used in combination with either plasmapheresis, rituximab, or 
high dose corticosteroids. No studies have shown that IVIg alone can reduce antibody 
burden pre-transplant, and outcomes following successful transplant are conflicting 
(Shehata et al., 2010; Nussinovitch & Shoenfeld 2008; Pisani et al., 1999; John et al., 1999). In 
the treatment of AMR, data are more robust; although again no studies have evaluated the 
utility of IVIg alone.  
6.2.3 Considerations with IVIg Use 
One unique consideration for the use of IVIg is product selection. Currently, seven FDA 
approved products are available for use. The major considerations for product selection are 
stabilizing agents/sugar contents, the IgA content, anti-A and anti-B isohemagglutinin 
concentrations, and availability of the product. One of the known adverse effects of high-
dose IVIg therapy is acute kidney injury (AKI). The likely contributors to AKI are sheer 
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protein load, osmolarity, and the excipient content of the product. Higher doses and 
therefore higher protein loads are associated with increased rates of adverse effects, as are 
products with sucrose as an excipient and those with high osmolarities. Efforts to decrease 
these effects include preparations that are liquid products with iso-osmolarity; 
unfortunately, the techniques utilized to achieve a more tolerable product have increased 
the titers of anti-isohemagluttinins. These products have therefore been associated with 
increased rates of clinically significant hemolysis. Clinical monitoring of patients with A, B, 
or AB blood types with prolonged duration or high doses of IVIg therapy is recommended 
(Jordan et al., 2011). Additionally, the IgA concentration varies across the available products. 
IgA depleted products must be used for patients with IgA deficiencies or antibodies to IgA, 
as IgA rich products may increase the risk of serious adverse reactions such as anaphylaxis. 
Finally, since IVIg is a pooled human product, it is limited by availability of donors and 
product demand. Subsequently, intermittent product shortage has been commonplace.  
Cytomegalovirus hyperimmune globulin (CMVIg, Cytogam), has a unique historical 
perspective in solid organ transplantation. While CMVIg has been studied as specific 
prophlyaxis for cytomegalovirus (CMV) disease, at one point in time, supply of IVIg was 
greatly limited. During this IVIg shortage, centers utilized the one IVIg product that was 
available: CMVIg. Subsequently, many centers established efficacy for CMVIg in 
desensitization and the treatment of AMR, and continue to use this specific product, despite 
no known or theoretical advantages over total IVIg, purely for immunoregulatory effects.  
6.3 Total Lymphoid Irradiation 
Total lymphoid irradiation (TLI) is low dose, targeted radiotherapy directed at major 
concentrations of lymph nodes across the body as well as the spleen. This traditionally has 
involved radiation exposure to 3 major areas across the body: the first being the chest above 
the diaphragm and below the base of the skull, a peri-aortic and splenic field, and finally a 
pelvic field to encompass all pelvic and inguinal lymph nodes. By irradiating these areas, 
theoretically a long-term decrease in antibody production would occur and mitigate the 
contribution of the B-cell immune system to rejection and any subsequent rejection episodes 
(Salter et al., 1995).  
TLI has been utilized in the treatment of rejection among solid organ transplant recipients 
for more than 20 years. The majority of data supporting TLI in the treatment of cardiac AMR 
comes from a single center, which reported TLI therapy for recurrent rejection or rejection 
with hemodynamic compromise in 73 patients between 1990 and 1996. TLI was delivered as 
80 cGy twice weekly for a total of 5 weeks, and was associated with a significant reduction 
in risk of rejection. This benefit was seen for approximately 4 years. No changes in long-term 
outcomes such as CAV or survival were seen. Unfortunately, myelodysplasia (MDS) or 
acute myelogenous leukemia (AML) did develop in 7 patients. This reported risk of 
leukemias has significantly limited the utility of TLI, and has lead to consensus 
recommendations to avoid its use in treatment of AMR (Kobashigawa et al., 2011). 
6.4 Photopheresis 
Extracoroporeal photopheresis (ECP) is a procedure similar to plasmapheresis where 
approximately 700mL of blood is removed and separated. The plasma is then incubated 
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with a photosensitizing agent, 8-methoxypsoralen, under UV-A radiation. This process 
covalently binds the photosensitizing agent to DNA and cell surface. These irradiated 
lymphocytes, monocytes, and dendritic cells decrease down-stream signaling for immune 
activation. Although the exact mechanisms are unknown, it is not believed that 
photopheresis has a majority of its benefit on B cells, but rather T cells; specifically T 
regulatory cells are affected. Each session is performed for approximately 1 – 3 hours, and 
sessions vary from daily to weekly.  
6.4.1 Data for photopheresis in heart transplantation 
ECP gained popularity in the heart transplant population for prevention of rejection when 
results from a multi-center randomized control trial evaluating standard 
immunosuppression with or without ECP found a 2 fold decrease in overall incidence of 
acute rejection. In this study, ECP was performed 2 days in a row every week for 4 weeks, 
then every 2 weeks for 2 months, and finally every month for 3 months (Barr et al., 1998). 
Unfortunately, there was no decrease in time to rejection or incidence of rejection with 
hemodynamic compromise. No studies to date have been performed to specifically evaluate 
the role of ECP in prophylaxis or treatment of AMR, although the Barr study did 
demonstrate a significant reduction in HLA antibody levels.  
6.4.2 Considerations with photopheresis use 
One consideration to be taken regarding photopheresis is the requirement for a central 
venous catheter; however, it is reported to be better tolerated than plasmapheresis, has 
minimal side effects, and has been shown to be safe in case reports of heart transplant 
recipients up to 3 years (Marques & Schwartz 2011). Reported adverse effects include 
malaise, low-grade fever, and gastrointestinal upset. Risks associated with invasive central 
lines, such as infection and thrombosis, are present as well. 
6.5 Cyclophosphamide 
Cyclophosphamide is an alkylating nitrogen mustard chemotherapeutic agent that was 
approved by the FDA in 1959 and has been used to treat a variety of neoplastic and 
autoimmune conditions. Its cytotoxic effects arise from intra- and interstrand DNA cross-
linking, leading to DNA inactivation and cell death; immunosuppression arises from 
selective suppression of B-lymphocyte activity as well as a general lymphopenia of both B 
cells and T cells. Theoretically, cyclophosphamide provides the advantage of avoidance of 
rebound B cell proliferation with more short-term strategies like plasmapheresis and IVIg 
that do not alter B cell production.  
6.5.1 Data for cyclophosphamide use in heart transplantation 
Several small case series have reported success with the use of cyclophosphamide and IVIg 
for desensitization prior to cardiac transplantation. The first reported a PRA decrease from 
64% to 14% with the combination of IVIg and cyclophosphamide, leading to successful 
transplantation (De Marco et al., 1997). More recently, Itescu and colleagues reported their 
experience with 16 sensitized LVAS patients awaiting cardiac transplantation, who received 
monthly treatment with cyclophosphamide 0.5 – 1 g/m2; all 23 patients were successfully 
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transplanted. No differences in adverse events compared to other sensitized patients 
occurred in this single center experience (Itescu et al., 2002).  
6.5.2 Considerations with cyclophosphamide use 
The clinical utility of cyclophosphamide, however, has been limited by the potential adverse 
effect profile and the increased utilization of B cell specific monoclonal antibodies. Primary 
toxicities associated with cyclophosphamide use include hematologic toxicities, 
hemorrhagic cystitis, and infertility/teratogenicity. Additionally, there is a risk of secondary 
malignancies such as leukemia, lymphoma, and skin cancers.  
6.6 Anti-Thymocyte Globulin (ATG and rATG) 
Anti-thymocyte globulins are polyclonal antibody products derived from either equine 
(ATG or Atgam®) or leporine (rATG or Thymoglobulin®) sources. Horses or rabbits are 
inoculated with human lymphocytes; serum is then removed from the animals and the 
antibodies against human CD3-bearing T cells are collected and purified. These products 
have been used generously throughout solid organ transplantation as both induction agents 
at the time of transplant as well as agents for the treatment of rejection, with a shift in 
clinical practice to almost exclusive use of the rabbit preparation based on studies showing 
better tolerability and potentially improved outcomes.  
6.6.1 Data for Anti-Thymocyte Globulin in heart transplantation 
While ATG has been utilized extensively in heart transplant recipients, no studies have 
evaluated their use in AMR; rather decreased overall rejection rates have been reported 
(Renlund et al., 1989; Ladowski et al., 1993; Macdonald et al., 1993; Schnetzler et al., 2002; De 
Santo et al., 2004). In both induction and rejection protocols, daily infusions are given for as 
little as 3 to at most 14 days. Additionally, no desensitization protocols have reported to 
utilize ATG. Given the lack of data, however, there is a theoretical benefit for the use of 
these polyclonal antibodies in the treatment of AMR or mixed ACR/AMR. While the 
majority of antibodies derived are against T-cells, many other cells are potentially affected, 
including B-cells, HLA heavy chains, plasma cells, platelets, white blood cells, red blood 
cells, and so on. In fact, the dose-limiting side effects are typically thrombocytopenia and 
leucopenia.  
6.6.2 Considerations with Anti-Thymocyte Globulin use 
In addition to pancytopenia, both products are associated with significant infusion 
reactions, cytokine release syndrome, and rarely anaphylactic reactions. These infusion 
reactions are significantly more pronounced in patients that have repeated previous 
exposure to either source animal and depending on the patient’s history may warrant 
avoidance of a particular product. Pre-medication prior to the infusion with steroids, 
acetaminophen, and diphenhydramine are recommended. More serious adverse effects 
include serum sickness, which presents as a delayed reaction with flu-like symptoms, 
lymphadenopathy, blurred vision, and rash. At the cellular level, increased levels of IgG, 
IgM, IgE, and acute phase reactants are seen with serum sickness reactions. The effects on 
humoral activation of serum sickness are as yet unknown. 
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6.7 Rituximab 
Rituximab is a chimeric humanized high-affinity monoclonal antibody targeted against the 
CD-20 receptor, which is borne by both B-cell progenitors and mature B-lymphocytes. B-cell 
depletion with rituximab occurs via three mechanisms: complement-dependent cytotoxicity, 
antibody-dependent cytotoxicity, and induction of apoptosis (Smith, 2003). Problematically, 
rituximab is only efficacious against circulating B-cells and progenitors and does not 
penetrate the spleen; thus, should be most efficacious against de novo antibodies which have 
been quickly recognized and intervened upon. In contrast, long-standing antibodies, such as 
those present in pre-sensitized candidates, should be relatively resistant to rituximab as the 
plasma cell from which they are generated is no longer circulating in the central 
compartment.    
6.7.1 Data for rituximab in heart transplantation 
Rituximab has been used across the spectrum of solid organ transplant recipients both for 
desensitization and AMR, albeit with minimal quality evidence of efficacy. The data 
describing rituximab use in cardiac transplantation is case report and case series in nature. 
Problematically, such case reports describe the addition of rituximab to traditional therapies 
such as TPE, IVIg, cyclophosphamide, and ATG complicating the evaluation of the efficacy 
of rituximab alone. Regimens used are also heterogeneous, ranging from 375 mg/m2 to 1 
gram fixed dose for 1 to 4 doses once weekly to twice monthly (Kcazmarek et al., 2007). 
Given this, it is nearly impossible to quantitate the potential benefit or role of rituximab for 
AMR in the cardiac allograft. Rigorous evaluation in a systematic fashion of rituximab 
therapy is desperately needed.  
6.7.2 Considerations with rituximab use 
Rituximab is generally well tolerated; however, some severe adverse effects have been 
reported. Leucopenia is relatively common after administration owing in large measure to 
suppression of B-lymphocyte differentiation. Hemodynamic effects, particularly transient 
hypotension, have been reported. Anaphylaxis is possible, but incredibly rare. Initially, 
small rituximab test-doses were required to evaluate anaphylaxis risk; however, these have 
been relegated due to poor positive predictive value. Since rituximab depletes CD-20 
bearing B-cell progenitors, it may be associated with an increased risk of recurrent 
infections; particularly those of a viral nature that rely on innate memory B-cells for 
protection such as CMV. The data regarding infectious risk in transplant recipients is 
qualitatively poor. In a case series of 8 cardiac transplant recipients, 3 patients developed 
infections (Garrett et al., 2005).  
7. Novel and experimental therapies 
Recently, alternatives to the previously discussed and more traditional therapies have 
emerged. These agents target plasma cells both in circulation and in the spleen, B-cell 
activating factors (BAFF), and the complement cascade. It should be noted that, at present, 
data supporting the use of these agents in cardiac transplantation is minimal. However, as is 
the case with many of the traditional therapies, these agents have both been used or are 
being actively studied in highly sensitized renal transplant recipients (RTR).  
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7.1 Plasma cell targeted agents 
Bortezomib, a 26S proteasomal inhibitor, results in the selective apoptosis of highly active 
plasma cells both in circulation and in the spleen. The proteasome is responsible for 
proteolysis of misfolded, damaged, or unneeded proteins within the cell; the inhibition of 
which leads to cell-cycle arrest and apoptosis (Everly et al., 2008). Only one case report has 
been published that describes the efficacy of bortezomib for refractory AMR in a cardiac 
transplant recipient (Eckman et al., 2009). Likewise, only one case series of 7 patients has 
been reported that describes the successful use of bortezomib for desensitization in 
candidates refractory to traditional therapies (Patel et al., 2010). The use of bortezomib is 
likely to expand in cardiac transplantation; particularly as longer-term safety data emerges. 
Belimumab is targeted at the BAFF B-lymphocyte stimulator (BLyS) and proliferation-
inducing ligand (APRIL). Targeting these tumor necrosis factor-family ligands ultimately 
results in the apoptosis of mature B-lymphocytes via suppression of BLyS and APRIL-
mediated antiapopototic effects during B-cell differentiation and maturation (Bossen & 
Schneider, 2006). This agent has shown promise in the treatment of systemic lupus 
erythematosis and is being actively trialed for desensitization in renal transplant candidates. 
7.2 Complement cascade targeted agents 
Eculizumab, a humaninzed anti-C5 monoclonal antibody, depresses the formation of the 
membrane attack complex (C5b9) in response to circulating DSA. There are no such reports 
describing the use of this agent in cardiac transplant recipients; however, 5 anecdotal cases 
are known to us. In all cases, eculizumab was paired either with traditional means of 
antibody depletion (TPE and IVIg), bortezomib, or both. A larger experience is known in 
renal transplantation. Eculizumab was given as prophylaxis of AMR in 10 highly sensitized 
RTR who received pre-transplant desensitization with TPE and IVIg. Half of the patients 
developed high DSA titers post-transplant, but no incidences of AMR were recorded in 12 
months of follow-up (Stegall, M., et al. 2009). Additionally, eculizumab was given as sole 
treatment to 16 highly sensitized RTR, and compared to a similarly sensitized cohort of 
patients who did not receive therapy. The incidence of AMR in the first post-transplant 
month was substantially less in the eculizumab patients (6.25% vs. 40%); however, 6 patients 
developed chronic AMR (Cornell et al., 2010). This suggests that eculizumab may be best-
utilized when paired with antibody-depletion measures, such as TPE. It should be noted 
that combining eculizumab with rituximab will render rituximab ineffective as its 
predominant pro-apoptotic mechanism is complement-mediated. 
Cinryze, human C1-esterase inhibitor, is collected from human donors in whole blood, 
purified via pasteurization and nanofiltration, and is currently approved for hereditary 
angioedema. The potential role of supraphysiologic concentrations of human C1-esterase 
inhibitor in the downregulation of the complement cascade notwithstanding, no reports 
currently exist that describe the role of Cinryze in transplant recipients. However, Cinryze is 
being actively studied in renal transplantation and may provide an alternative for C5b9 
inhibition. 
8. Conclusions 
Antibody-mediated rejection is a poorly characterized, understood, and studied disease 
process in solid organ transplantation today. There are active efforts across all organ 
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systems to better-define the pathogenesis of DSA in the development of AMR, the long-term 
consequences of its development, and the best methodology to screen and manage patients 
who are pre-sensitized. Relative to AMR in the heart transplant community, until the newly 
derived definition of AMR is uniformly adopted and utilized, it is unlikely that quality 
retrospective research will be completed on a large scale. However, there are ongoing efforts 
at high-volume centers to study the novel and experimental therapies in an effort to enhance 
transplantability of highly-sensitized candidates and manage AMR when it subsequently 
develops. Traditional measures, such as TPE and IVIg, remain the cornerstone of AMR 
therapy. TLI, photophoresis, and cyclophosphamide have fallen out of favor due to adverse 
effects or lack of efficacy. The role of rituximab is unclear as it has never been subjected to 
rigorous clinical evaluation and has mechanistic disadvantages relative to its novel 
alternative, bortezomib. Finally, the horizon is bright for the use of complement-antagonists 
to reshape how we manage pre-sensitized patients in an effort to enhance their candidacy 
for transplantation.  
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